Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41

NCT00216060 is registered in ClinicalTrials.gov with Christopher Sweeney, MBBS as lead sponsor.

NCT NCT00216060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Lead sponsor
Christopher Sweeney, MBBS
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2003
Completion date
March 31, 2008
Enrollment
63 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer